An evaluation of tedizolid for the treatment of MRSA infections

Hall, Ronald G.; Smith, W. L.; Putnam, William C.; Pass, Steven E.

doi:10.1080/14656566.2018.1519021

Cited by 24 publications

(10 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Marketed oxazolidinones are weak, reversible inhibitors of monoamine oxidase (MAO) in vitro 48. In this regard, the available data suggest a low incidence of serotoninergic syndrome in patients treated with tedizolid, although the fact that patients treated with serotoninergic agents were excluded from ESTABLISH-1 and ESTABLISH-2 does not allow to completely exclude possible interactions 48,49. No increase in blood pressure were observed in subjects who concomitantly received tyramine or pseudoephedrine 48,50,51…”

Section: Methodsmentioning

confidence: 99%

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Bassetti¹,

Castaldo²,

Carnelutti³

et al. 2019

View full text Add to dashboard Cite

Introduction Tedizolid phosphate is an oxazolidinone approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) and active against methicillin-resistant Staphylococcus aureus . Aims The objective of this article was to review the evidence for the efficacy and safety of tedizolid phosphate for the treatment of ABSSSI. Evidence review Approval of tedizolid phosphate for the treatment of ABSSSI was based on the results of two phase III randomized controlled trials, ESTABLISH-1 (NCT01170221) and ESTABLISH-2 (NCT01421511), comparing 6-day once-daily tedizolid vs 10-day twice-daily linezolid. In ESTABLISH-1, noninferiority was met with early clinical response rates of 79.5% and 79.4% in tedizolid and linezolid groups, respectively (difference 0.1%, 95% CI –6.1% to 6.2%, with a 10% noninferiority margin). In ESTABLISH-2, noninferiority was met with 85% and 83% rates of early clinical response in tedizolid and linezolid groups, respectively (difference 2.6%, 95% CI –3.0% to 8.2%). Pooled data from ESTABLISH-1 and ESTABLISH-2 indicated a lower frequency of thrombocytopenia in tedizolid-treated than in linezolid-treated patients. Conclusion Tedizolid offers the option of an intravenous to oral switch, allows once-daily administration, and presents lower risk of myelotoxicity when a 6-day course is used for the treatment of ABSSSI. Greater economic cost associated with this antibiotic could be offset by its shorter treatment duration and possibility of oral administration in routine clinical practice, although either sponsored or nonsponsored postmarketing observational experience remains essential for ultimately confirming the effectiveness and tolerability of tedizolid outside clinical trials.

show abstract

Section: Methodsmentioning

confidence: 99%

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Bassetti¹,

Castaldo²,

Carnelutti³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, AMR S. aureus species are one of 12 families of priority pathogenic bacteria listed by the World Health Organization (WHO) for which antibiotics are urgently needed (World Health Organization [WHO], 2017). Several new currently approved oxazolidinone class antibiotics, including Sivextro (Hall et al, 2018), tigecycline (Hall et al, 2018), and LCB01-0371 (Jeong et al, 2010) to eradicate S. aureus species resistant to last-resort antibiotics have been developed. However, it is possible that bacteria might continue to evolve to evade this new class of lastresort antibiotics, and it takes much time to find other alternatives and their mechanism of action in response to a newly generated resistant strain.…”

Section: Introductionmentioning

confidence: 99%

Easy One-Pot Low-Temperature Synthesized Ag-ZnO Nanoparticles and Their Activity Against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus

Naskar

Lee

Kim

2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) is widely acknowledged as a global health problem, yet the available solutions to this problem are limited. Nanomaterials can be used as potential nanoweapons to fight against this problem. In this study, we report an easy one-pot low-temperature synthesis of Ag-ZnO nanoparticles (AZO NPs) and their targeted antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) strains. The physical properties of the samples were characterized by X-ray diffractometry (XRD), transmission electron microscopy (TEM), and X-ray photoelectron spectroscopy (XPS). Furthermore, minimum inhibitory concentration (MIC), zone of inhibition (ZOI), and scanning electron microscopy (SEM) images for morphological characterization of bacteria were assessed to evaluate the antibacterial activity of AZO NPs against both Gram-negative [Escherichia coli (E. coli) and Acinetobacter baumannii (A. baumannii) standard and AMR strains] and Gram-positive (S. aureus, MRSA3, and MRSA6) bacteria. The AZO NPs showed comparatively better antibacterial activity against S. aureus and MRSA strains than Gram-negative bacterial strains. This costeffective and simple synthesis strategy can be used for the development of other metal oxide nanoparticles, and the synthesized nanomaterials can be potentially used to fight against MRSA.

show abstract

“…Fourth, studies using C5a to investigate its effects in assays of neutrophil function/dysfunction should take care in design as chemotactic agents can have contrasting effects and lead to neutrophil priming/de-priming responses 63 – 65 . Finally, studies such as this could be applied to the next generation of novel oxazolidinone and anti-staphylococcal agents, such as tedizolid, which has potential for treating MRSA infections 66 .…”

Section: Discussionmentioning

confidence: 99%

Contrasting effects of linezolid on healthy and dysfunctional human neutrophils: reducing C5a-induced injury

Evans

Roberts

Morris

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Methicillin-resistant Staphylococcus aureus (MRSA) is an important cause of ventilator-associated pneumonia (VAP). Patients with VAP have poorly functioning neutrophils, related to increased levels of the complement fragment C5a. The antibiotic linezolid has been useful in controlling MRSA-related VAP infections; however clinical benefit does not always correlate with antimicrobial effect, suggesting the possibility of immunomodulatory properties. Here the effects of linezolid on healthy and dysfunctional neutrophils (modelled by C5a-induced injury) was investigated. Functional assays (killing, phagocytosis, transmigration, and respiratory burst) were used to assess the effects of pre-, co- and post-incubating linezolid (0.4–40 mg/L) with healthy neutrophils relative to those with C5a-induced injury. C5a decreased neutrophil killing, and phagocytosis of MRSA. Furthermore, C5a significantly decreased neutrophil transmigration to IL-8, but did not affect respiratory burst. Co-incubation of linezolid significantly improved killing of MRSA by dysfunctional neutrophils, which was supported by concomitant increases in phagocytosis. Conversely linezolid impaired killing responses in healthy neutrophils. Pre- or post-incubation of linezolid prior or following C5a induced injury had no effect on neutrophil function. This study suggests that linezolid has immunomodulatory properties that protect human neutrophils from injury and provides insight into its mode of action beyond a basic antibiotic.

show abstract

An evaluation of tedizolid for the treatment of MRSA infections

Cited by 24 publications

References 54 publications

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

<p>Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy</p>

Easy One-Pot Low-Temperature Synthesized Ag-ZnO Nanoparticles and Their Activity Against Clinical Isolates of Methicillin-Resistant Staphylococcus aureus

Contrasting effects of linezolid on healthy and dysfunctional human neutrophils: reducing C5a-induced injury

Contact Info

Product

Resources

About